1179 related articles for article (PubMed ID: 28216140)
21. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
22. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
23. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
Ozcan HEA; Anuk T; Ozden O
Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
[TBL] [Abstract][Full Text] [Related]
24. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
25. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
[TBL] [Abstract][Full Text] [Related]
26. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
27. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa.
Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH
Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717
[TBL] [Abstract][Full Text] [Related]
29. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
[TBL] [Abstract][Full Text] [Related]
30. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
31. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
Burjonrappa SC; Reddimasu S; Nawaz Z; Gao X; Sharma P; Loggie B
Indian J Cancer; 2007; 44(1):1-5. PubMed ID: 17401217
[TBL] [Abstract][Full Text] [Related]
32. The relationship of endocrine cells, dysplasia and carcinoembryonic antigen in Barrett's mucosa to adenocarcinoma of the oesophagus.
Griffin M; Sweeney EC
Histopathology; 1987 Jan; 11(1):53-62. PubMed ID: 2881873
[TBL] [Abstract][Full Text] [Related]
33. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
[TBL] [Abstract][Full Text] [Related]
37. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
[TBL] [Abstract][Full Text] [Related]
39. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
40. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
